BGI Genomics Co., Ltd. (300676.SZ)
CNY 45.76
(-0.72%)
CNY 45.76
(-0.72%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.09 Billion CNY | 15.87% |
| 2022 | 946.21 Million CNY | 8.74% |
| 2021 | 870.17 Million CNY | -33.2% |
| 2020 | 1.3 Billion CNY | 2200.87% |
| 2019 | 56.61 Million CNY | 82.25% |
| 2018 | 31.06 Million CNY | -19.76% |
| 2017 | 38.71 Million CNY | 1190.47% |
| 2016 | 3 Million CNY | -63.09% |
| 2015 | 8.12 Million CNY | -12.0% |
| 2014 | 9.23 Million CNY | 277.04% |
| 2013 | 2.45 Million CNY | 172.22% |
| 2012 | 900 Thousand CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 1 Billion CNY | -17.27% |
| 2024 Q1 | 1.21 Billion CNY | 10.4% |
| 2024 Q3 | 347.54 Million CNY | -59.96% |
| 2023 Q2 | 1.01 Billion CNY | 10.37% |
| 2023 Q4 | 1.09 Billion CNY | 1.92% |
| 2023 FY | 1.09 Billion CNY | 15.87% |
| 2023 Q1 | 919.81 Million CNY | -2.79% |
| 2023 Q3 | 1.07 Billion CNY | 5.97% |
| 2022 Q4 | 946.21 Million CNY | 264.34% |
| 2022 Q3 | 259.7 Million CNY | 2.95% |
| 2022 Q2 | 252.27 Million CNY | -69.96% |
| 2022 FY | 946.21 Million CNY | 8.74% |
| 2022 Q1 | 839.74 Million CNY | -3.5% |
| 2021 Q1 | 1.18 Billion CNY | -8.91% |
| 2021 Q4 | 870.17 Million CNY | -4.01% |
| 2021 Q3 | 906.5 Million CNY | -1.85% |
| 2021 FY | 870.17 Million CNY | -33.2% |
| 2021 Q2 | 923.57 Million CNY | -22.16% |
| 2020 Q4 | 1.3 Billion CNY | 26.06% |
| 2020 FY | 1.3 Billion CNY | 2200.87% |
| 2020 Q1 | 427.41 Million CNY | 654.97% |
| 2020 Q2 | 994.68 Million CNY | 132.72% |
| 2020 Q3 | 1.03 Billion CNY | 3.89% |
| 2019 Q4 | 56.61 Million CNY | 0.0% |
| 2019 FY | 56.61 Million CNY | 82.25% |
| 2019 Q3 | - CNY | 0.0% |
| 2019 Q2 | - CNY | -100.0% |
| 2019 Q1 | 24.08 Million CNY | -22.48% |
| 2018 Q4 | 31.06 Million CNY | 34.28% |
| 2018 Q1 | 40.19 Million CNY | 3.82% |
| 2018 Q2 | 28.94 Million CNY | -27.99% |
| 2018 FY | 31.06 Million CNY | -19.76% |
| 2018 Q3 | 23.13 Million CNY | -20.08% |
| 2017 FY | 38.71 Million CNY | 1190.47% |
| 2017 Q3 | 29.69 Million CNY | 30.36% |
| 2017 Q1 | 3 Million CNY | 0.0% |
| 2017 Q2 | 22.77 Million CNY | 659.32% |
| 2017 Q4 | 38.71 Million CNY | 30.37% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 Q4 | 3 Million CNY | 0.0% |
| 2016 FY | 3 Million CNY | -63.09% |
| 2015 Q2 | 13.09 Million CNY | 0.0% |
| 2015 Q4 | 8.12 Million CNY | 0.0% |
| 2015 FY | 8.12 Million CNY | -12.0% |
| 2015 Q1 | 13.09 Million CNY | 0.0% |
| 2014 FY | 9.23 Million CNY | 277.04% |
| 2013 FY | 2.45 Million CNY | 172.22% |
| 2012 FY | 900 Thousand CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 4.29 Billion CNY | 74.453% |
| Hangzhou Tigermed Consulting Co., Ltd. | 3.34 Billion CNY | 67.238% |
| Dirui Industrial Co.,Ltd. | 714.1 Million CNY | -53.535% |
| Beijing Strong Biotechnologies, Inc. | 1.13 Billion CNY | 3.454% |
| Medicalsystem Biotechnology Co., Ltd. | 108.17 Million CNY | -913.581% |
| Maccura Biotechnology Co.Ltd | 665.16 Million CNY | -64.832% |
| Guangzhou Wondfo Biotech Co.,Ltd | 599.53 Million CNY | -82.875% |
| Guangdong Hybribio Biotech Co.,Ltd. | 56.65 Million CNY | -1835.315% |
| Amoy Diagnostics Co., Ltd. | 108.34 Million CNY | -911.944% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 374.62 Million CNY | -192.669% |